Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

<p style="text-align:justify;"> To improve strategies for the treatment of BRAF-mutant advanced colorectal cancer (aCRC) patients, we examined individual data from patients treated with chemotherapy alone in three randomised trials to identify points on the treatment pathway where o...

Full description

Bibliographic Details
Main Authors:	Seligmann, JF, Fisher, D, Smith, CG, Richman, SD, Elliott, F, Brown, S, Adams, R, Maughan, T, Quirke, P, Cheadle, J, Seymour, M, Middleton, G
Format:	Journal article
Language:	English
Published:	Oxford University Press 2016

Similar Items

2530
by: Bernadette McKinney
Published: (2017-09-01)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
by: Adams, R, et al.
Published: (2017)

BRAF and NRAS locus-specific variants have different outcomes on survival to colorectal cancer
by: Summers, MG, et al.
Published: (2016)

FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
by: Adams, R, et al.
Published: (2016)

Targeting mutant BRAF in colorectal cancer
by: Carroll David, et al.
Published: (2013-01-01)

Panitumumab in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer: Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
by: Seymour, M, et al.
Published: (2011)

The unfolded protein response: a novel therapeutic target for poor prognostic BRAF mutant colorectal cancer
by: Forsythe, N, et al.
Published: (2018)

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
by: Susan D. Richman, et al.
Published: (2011-01-01)

BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy
by: Vinay K. Pattalachinti, et al.
Published: (2025-02-01)

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT
by: Louise C Brown, et al.
Published: (2022-12-01)

Preclinical efficacy of carfilzomib in BRAF‐mutant colorectal cancer models
by: Federica Maione, et al.
Published: (2024-06-01)

Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers.
by: Catherine E Bond, et al.
Published: (2012-01-01)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
by: Elisa Grassi, et al.
Published: (2021-06-01)

Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
by: Maughan, T, et al.
Published: (2009)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
by: Yasar Subutay Peker, et al.
Published: (2018-01-01)

DEFICIENT MISMATCH REPAIR (DMMR) AND BRAF MUTATION (MT) STATUS IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC): A META-ANALYSIS OF THE CAIRO, CAIRO2, COIN AND FOCUS STUDIES
by: Venderbosch, S, et al.
Published: (2012)

Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer - Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification
by: Middleton, G, et al.
Published: (2011)

Pipeline electrical and instrumentation : switches and transmitters (CT25.30. and 31)
by: 599270 National Center for Construction Education and Research
Published: (2002)

Design of Collection Module of Underground Personnel Information Based on CC2530
by: ZHENG Mao-quan, et al.
Published: (2012-06-01)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
by: Seymour, M, et al.
Published: (2013)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial
by: Seymour, M, et al.
Published: (2013)

Incidence and prognostic factors in patents (pts) with mutant BRAF (mBRAF) metastatic colorectal cancer (mCRC) in Russia
by: M. Yu. Fedyanin, et al.
Published: (2021-06-01)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
by: Ting Xu, et al.
Published: (2022-06-01)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
by: Ting Xu, et al.
Published: (2023-05-01)

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.
by: Smith, C, et al.
Published: (2013)

Design of Mine-used Wireless Roof Pressure Sensor Based on CC2530
by: WU Yao-ming, et al.
Published: (2012-12-01)

THROMBOCYTOSIS AS A PREDICTIVE AND PROGNOSTIC MARKER IN ADVANCED COLORECTAL CANCER (ACRC): RESULTS OF THE MRC COIN TRIAL EXPLORED
by: Maughan, T, et al.
Published: (2010)

RNF43 is associated with genomic features and clinical outcome in BRAF mutant colorectal cancer
by: Peipei Shang, et al.
Published: (2023-06-01)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
by: Evelina Miele, et al.
Published: (2020-02-01)

Braf-Mutant Melanomas: Biology and Therapy
by: Elvira Pelosi, et al.
Published: (2024-12-01)

Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla R, et al.
Published: (2013-12-01)

2530 Relationship between preexisting pain and completion of a community-based wellness program
by: Chantay Young, et al.
Published: (2018-06-01)

SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer.
by: Ida V Lundberg, et al.
Published: (2014-01-01)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
by: Pan JH, et al.
Published: (2018-08-01)

Identification of anticancer drugs to radiosensitise <i>BRAF</i>-wild-type and mutant colorectal cancer
by: Rebecca Carter, et al.
Published: (2019-06-01)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
by: Maughan, T, et al.
Published: (2010)

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study.
by: Wood, G, et al.
Published: (2017)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
by: Eva Marie Erfurth, et al.
Published: (2024-12-01)

Mutant-selective degradation by BRAF-targeting PROTACs
by: Shanique Alabi, et al.
Published: (2021-02-01)

Preoperative prediction of early recurrence in patients with BRAF mutant colorectal cancer using a intergrated nomogram
by: Zhenbin Jin, et al.
Published: (2024-10-01)